The merged entity would not have the ability to foreclose market access to lactase
manufacturers. First, the parties submit that the merged entity will not have a significant market power in the downstream market both globally and in the EEA to engage in a customer foreclosure strategy. 256 Second, […] Manufacturers (that supply the Parties with non-GM produced lactase) would not be foreclosed from a substantial part of the market. As it currently stands, the Parties’ combined shares for the distribution/commercialization of non-GM produced lactase account for [5-10]% and [5-10]% of the global and EEA sales in the overall lactase market respectively.
257 Third, […] Manufacturers could also choose to distribute their product directly, as they already do in some jurisdictions258 or through a number of distributors they can easily turn to.259 The Parties note that, even if there was an ability to foreclose, it would not be merger specific since pre-Transaction, the Parties supply GM lactase manufactured by Novozymes and the non-GM lactase of the […] Manufacturers and intend to continue to do so post-Transaction.260